Diltiazem Hydrochloride Extended-Release Capsules Recalled for Manufacturing Impurity
Glenmark Pharmaceuticals is recalling 25,584 bottles of Diltiazem Hydrochloride Extended-Release Capsules 120 mg nationwide due to a manufacturing impurity above FDA-recommended limits. The affected medication was distributed throughout the United States.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving a manufacturing deviation with the presence of a nitrosamine impurity above recommended levels. No illnesses or injuries have been reported; therefore, this meets the criterion for a risk-of-harm product where injury has not yet been reported, resulting in a High severity score.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling 25,584 bottles of Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg due to a current Good Manufacturing Practice (cGMP) deviation.
The affected product contains N-nitroso-Desmethyl-Diltiazem impurity above the FDA-recommended interim limit. The recall involves the following lot numbers: 17222470, 17230680, and 17222547 (expiration 11/30/2024); 17230304 (expiration 12/31/2024); and 17230598 (expiration 02/2025). The product NDC is 68462-562-01.
The affected medication was distributed nationwide in the United States. This is classified as a Class II recall by the FDA.
The recalled product
- Product
- DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE)
- Brand
- DILTIAZEM HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- nitrosamine-impurity
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot #: 17222470
- 17230680
- 17222547
- Exp. Date 11/30/2024
- 17230304
- Exp. Date
- 12/31/2024
- 17230598
- 02/2025.
UPCs (3)
- 0368462562017
- 0368462851012
- 0368462850015
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DILTIAZEM HYDROCHLORIDE
- HighGlenmark Diltiazem Extended-Release Capsules recalled for manufacturing deviations
FDA (Drugs) · 2025-04-16
- HighDiltiazem Hydrochloride Capsules Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem extended-release capsules recalled for manufacturing impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Capsules Recalled Due to Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighPrescription Drug Diltiazem Hydrochloride Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27